3,507,055 Shares in Tempest Therapeutics, Inc. (NASDAQ:TPST) Acquired by Versant Venture Management LLC

Versant Venture Management LLC bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,507,055 shares of the company’s stock, valued at approximately $2,927,000. Tempest Therapeutics comprises 3.4% of Versant Venture Management LLC’s portfolio, making the stock its 6th largest position. Versant Venture Management LLC owned 8.04% of Tempest Therapeutics at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in the company. XTX Topco Ltd acquired a new position in shares of Tempest Therapeutics in the 3rd quarter valued at about $34,000. Virtu Financial LLC acquired a new position in Tempest Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Geode Capital Management LLC lifted its stake in Tempest Therapeutics by 42.7% in the third quarter. Geode Capital Management LLC now owns 220,067 shares of the company’s stock valued at $308,000 after buying an additional 65,826 shares during the period. Institutional investors own 22.52% of the company’s stock.

Tempest Therapeutics Stock Down 0.2 %

Shares of TPST stock opened at $0.82 on Wednesday. Tempest Therapeutics, Inc. has a 52 week low of $0.70 and a 52 week high of $6.00. The firm has a 50 day moving average of $0.87 and a 200-day moving average of $0.99. The company has a market cap of $35.93 million, a price-to-earnings ratio of -0.54 and a beta of -1.83.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.